FDA advisory panel backs easing peptide rules

An FDA advisory committee voted to potentially allow six peptides—BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—to be dispensed by compounding pharmacies, pending further approval. These peptides are not yet officially approved but are popular in wellness circles for their purported health benefits, including healing, anti-inflammatory effects, and anti-aging. The FDA still needs to formally adopt the recommendations, which could take over a year, and there is speculation that an HHS Secretary may expedite the process.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل